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GHAPl'EH I 
IN'.l'HOJJUG'I'ION 
Pax·enteral ttera1w is a means by which dru(';s, 
nutrients, and fluids may be given to a patient, usually 
if------t=h""r_.,o._...u,gh a vein or into a muscle, or more precisel~'L,,_'~'u~·n~·'d~e~r ____ _ 
or through one or more lay·ers of the skin or mucous mem-· 
( ' ). . brane _.L " 1' The growth and development of parenteral therapy, 
like many other proced.ur·es in medicine, have progressed 
slowly and erratically throughout its history. Acl.van:-;emeut 
ha.s been stimulated., in many eases, through a basic need. 
for a new and. better way. An excellent example of this if: 
the fa.:irly recent development of intravenous hyperalimen--
tation b;y Dudrick (2). 
Intravenous therapy followed the discovery of the 
circulation of blood by Harvey when Sir Christopher Wren 
attemp·t;ed. to give intravenous injections of medication to 
dogs, apparently with some success (3). Little did he know 
of the tremendous field into which parenteral therap;y would 
develop. 
Probably the first recorded successful transfusion 
occurred in Paris by Denys in 1666. This transfusion into 
a human being was done using the blood of a calf to treat 
an idiot, at the request of the idiot's wife. The first 
S'.lccess.ful experimenter to transfuse blood from one human 
1 
I 
l. 
1' I 
being into another was Blundell of England in 1821+. ·Blundell 
believed that small transfusions o:i' blood might save some of 
his cases of severe post-partum uterine hemorrhage which 
usually t erminat eo. in death ( lJ-). 
In E<'J.inburgh, in 1832, during a cholcn~a epidemic:, 
latta, in a desperate attempt, administered a solution of 
sodium chloride and sodium bica.rbonate t;o his patients. 
The dramatic improvement tha.t resulted initiated. the real 
start and development of int:ravenous therapy (5)., Parenteral 
administration, particularly intravenous therapy, was origi-
nally pioneered in the United States in the middle 1800's 
and developed steadily as new concepts of aClministrat5 on., 
aceurae~r of (Jr)sc._~_go ;- ahd better analytical methods for ~--:hE1 
investigation o.f body fluids were developed (6). 
i'he benefits of intravenous therapy have become 
more and more apparent over the years. Medications can 
be given rapiCJ.ly with an expectant rapid onset of action. 
·The response to the drugs or fluids can often be closely 
controlled by regulating the dose or x·ate of administration. 
Frequently, adequate blood and tissue level,s needed to erad.i-
cate many serious infections can be reached only by this 
route. Intravenous therapy is an especially· approp7.:iate 
method when the use of the oral tract, for one reason or 
another, cannot be used. 
The development o1· intravenous therapy, however 1 
did not proceed without its difficulties.. Problems of 
allergic reactions, incompatible blood groups, ba<:terial 
-··-~-­
~-~--
contamination, particulate matter, th.rombOJ?hlebitie 
oyndromes, stability of solutions, and incompatibilities 
of admixtures soon became apparent. 'l'he purpose of this 
paper is to explore certain aspects of the latter problem, 
i.e., intravenous incompatibilities. 
Problems of Intravenous Admixtures 
An ineompatibility has been aptly defined by 
3 
Parker (7) as, "the failure of a drug or drur_,; mixture to 
combine with another drug in an expected or desired manner." 
Useful information about intravenous incompatibilities in 
only slo~Jly being developed, both for investigational and 
commercially available drugs. The reasons :for:- this are 
probably man:y. It 1vould appeg_r that manufacturers woulo. 
ll' Ve a~c•e·r)·le<·] ++e Cha"l] n~o·~ o·f '"~~hep·'Lnrr t"J·l· S "nf'orma+-; 0~' 0. , ..,,_. ·;, .. "' ·;. ,,,_;,· .•.. ~··~-\•.u-l;)r;.' ' .. t:,ct.l .... l ~·· ·-o .1 ,_ ..!.. __ ~ '-~- ·····; 
at least i.n ;~espect to their own products. However, the 
problems of intravenous solution incompatibilities of drug 
additives consist of the problems of tt~o or more drugs 
interacting with each other physically, chemically, or 
therapeutically in one or more different infusion fluids. 
When drugs other than a manufacturer's ovm products are 
involved, the problems of liabiiity concerning another 
company's drugs comes into focus. While the manufacturer 
may have information on his product, he may not know ~That 
ethel' drugs a physician vTill prescribe to be in an admix-
ture with his drug. Can one manufacturer assume the 
responsibility of another manufacturer's products? Accord-
ing to Superstine (8), the answer appears to be no, in that, 
"manufacturers of drugs intended for intravenous use may 
be responsible only if and when their preparations are 
used according to their instructions." In an attempt to 
ansv;er, or rather avoid, the problem of intravenous incom-
patibilities, a number of drug companies have a.dvised, in 
their product information booklets a.nd. packa.go inr;erl:;s, ,] 
I ~ that their parenteral products be used. immedi.ately a.fter 
l~----~l'Ef'CUirrrt-.i L. u:t±o1J:-arD.."t--"G-h--a:t-t-:lt~d-c'rm±-xt-i:t-:re-eJf-----'rro::e-e::-n{~-e-:t·a-±-m-e-c1--:-t---·-----~ 
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! 
., 
I 
cations be avoidecl whenever possible (9). 
Another problem that should be considered with ree;ard 
to the manufacturers and the question of intravenous admix-· 
tures is their reluctance to supply vital informa.tion to 
other :r·e::;earche:rs working in the area of admixture compati·-
·:;~·'hili ti e.s:: IJti·;:;:i olais (1
"' } 
writes a lette:c- with a question to a pharmaceutical company~ 
the letter is often referred to the legal d.epartment because 
the company is concerned. about the problems that it may 
encounter v:ith the F.D.A. in giving an answer. He explains 
that, instead of going to the scientific o.ivision of the 
eompany, initial drug inquiries often end in the legal office 
because of the restrictions the government puts on them con~ 
cerning distribution of unapproved drug information. Many 
times, the net result is no anS\~er. The company explains 
that it cannot give the information without having it 
clea.red through the "red tape" of the F.D.A. In response 
to the comments of Latiolais, Sleezer (10) of Hoffman-I"aRoche 
states that, "perhaps ninety per cent of the things that you 
do as a hospital pharmacist is legall;y putting the 
pharmaceutieal manufacturer in the position of having 
an N.D.A. on their hands when they e;ive you any comment." 
If a manufacturer disseminates, either· privately or 
publicl;y s information regarding the compati biJ.i.t;y of its 
products ~lith those of another, the s:i:tuation might be 
considered tantamount to promoting a neH product. Such 
admixture combinations might come VJithin the leg,"'a,..l'---'d"'e_,.J:,_.,'icc:-::__ ___ _ 
nition of nevJ drugs and require the submission of' exten-
sive laboratory, animali and clinical studies. Meyers (11) 
states that; "it would be an impossible burden for each 
manufacturer to carry out such studieE1 for every possible 
·combino.t;:Lon of his particular prnp;J.rat:Lon. with other 
in,jectables." 
Thus, only to a very limited extent, have manu-
facturers accepted the responsibility for determining the 
compatibility of intravenous drug admixtu:r:es. The few 
companies that have contributed work in this area have 
been, for the most part, those that manufacture the various 
infusion fluids. One of the better examples of this is the 
~rork that resulted in the charts published by Abbott 
Laboratoriesa v1hich describe compatibilities and incompati-
bilities of drugs in their solutions. The early work done 
in developing these was by Kirkland (12), ~rho conducted 
his studies on behalf of the company. The main disadvantages 
a - Abbott Laboratories, North Chicago, Ill. 
-----~--------
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of these charts, as well as the other early charts and. 
tables rleveloped. from the work of the few companies anrl 
the individual prbrate investigators, a.re e.speciaU.y 
apparent when one attempts to extract some useful. informa-
tion from them. Not only are they seriously deficient with 
regard. to specifir)s about the aiJin.ixtures but, for· the most 
part;~ they include only information conce:rrd.ng so-ealled. 
where combinations have been designated as "compatible," 
Webb (13) believes that the word "soluble" would be more: 
appropriate. Usually there are no claims made regarding 
chemical or pharmacologic compatibilities. Meyers (14) 
admord.tl~1es; "when compatibility tables anc1 charts are 
cal Qr chemical interactions ••• the information is in 
itself a possible hazard to the patient i1ho will receive 
the extemporaneously mixed injection." 
To add to this problem, the authors of the charts 
and tables usually summarize with an attempt to discharge 
any liability for the information by enclosing a a.isclaimer. 
lilhil.e this may be consistent with good legal practice, it 
does not appear that these escape clauses are the answer to 
the manufacturer's responsibility (15). The one good attri-
bute of the various charts is that there has been an attempt 
to centralize the available data regarding the physical 
incompatibilities into a more workable form. 
Another reason for the lack o.f information on 
---~~-
intravenous incompatibilities is probably because of the 
enormous number of possible admixture combinations. The 
combination of drugs extemporaneously tailor--made a.t the 
direction of the physician is extensive. Using a. computer, 
in 1965 Dunworth and Kenna (16) determined that for the 24 
most commonly used medications which wc-lre add.ed t;o intra-
venous solutions at their hoGpital, over 11,000 unique 
Coml)l. n,>_;,'Lt)n_~, l. n P. al· r". ·t;h,...ee'" and f'o·llv''' '•J"·~e ·nr)"SJ. ble ~ y. .. - . - ~ ... '" ~ ' ~ ., "'·'· ,, ... u • • 
Misgen (1'7) noted that with a given 500 drugs, 124,7?5 
different combinations of two drugs each vvere possible. 
He continued that, if these 500 drugs were mixed in com-
'} 
' 
'b:inations of more than two, then the number of possibilities 
becomes astronomicaL. Acc:o:ccl:Lng t:o l0le:Ln (18), if 100 drugs 
are cross-matched three at a time, 161, 7Lfl different c:om-
bino.tions are possible. These figures alone ru:-e immense. 
The other possibilities of mixing the drugs in the various 
o.ifferent commercial solutions available, not to mention 
different doses of the various drugs, must then be super-
imposed on those statistics. 
\'lhen one considers that even for one particular 
drug, the formulation may differ from manufacturer to manu-
facturer o.ue to the addition of different buffers, solubi-
lizers, preservatives, and anti-oxidants, ~rhich also can 
contribute to a chemical or biological incompatibility~ 
another complication is introduced. This is especially 
true when one considers commercially available trade name 
or proprietary products in contrast to the generic or 
ii 
~ 
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non-proprietary brands that are used more and more commonly. 
Recently, studies are becoming available to con:fil'm the 
belief tb.at products from different· manufacturers that were 
once claimed to be generic equivalents, are in fact not 
equivalent due to differences in acl_juvants used and in 
methods of manufacturing. Wagner (19) has recently list eo. 
the 12 currently controlled studies in 1·1hich ·t~-10 or more 
commercial <irug products, containing the sa.me drug,___,i'"'n,___.t~h=e~. ____ _ 
same type of dosage form and comparecl in man, are summarized .• 
Large statistically significant d.ifferences betvreen a par-
ticular product manufactured by different companies were 
sometimes quite apparent. 'l'he differences may have been 
the resul.t. o.f ::l.ifferent adjuvants used in formulation of 
the products, as well as difi'ererrt methods of p:•od.!Jction 
err.ployed. 
Another problem to be considered is that, even 
among a mmmfacturer' s own products, a specific product 
may differ from lot to lot. ·A good example of this was 
illustrated in "Olin-Alert" (20). Certain physicians in 
Australia were having difficulties 1vith some of their 
patients on diphenylhydantoin. These patients were experi-
encing signs of overdosage and no reason could be given 
until it wns found out that the manufacturer had changed 
the excipient present in the capsules manufactured in 
Southeast Asia. This change caused a greater percentage 
of the dose to be absorbed., yielding higher blood levels 
of the drug followed by signs of toxicity. 
'! 
·~. 
Variations among a company's own products 01~ those 
of different companies frequently result from the lack of 
rigid. specification in tho official monographs that set 
standards for most products available. The official mono-
graphs do not specify what adjuvants may or may not be used 
in the d.osage form of a dru.g, nor do they specify any par·· 
t:i.eular manufacturing methods. Thus, it is no surprise 
thPt prod.u.c:ts can differ widely from manufacturer to manu-
facturero 
With the advent of increasecl implementation of 
centralized int;ravenous additive programs, a service 1vhich 
complies ~:ith Accredi:l;aticm Standards set by the J"oint 
Commission on Acered:i.tation of Hospitals (21)~ orders from 
physicians .fo:r. intravenous ao.m'ixtures B.re receiYing c J.oser 
scrutiny and. evaluation. Few ph;y-sicians or nurses have 
0 ) 
sufficient knowledge of chemistry to apprecia:!;e all possible 
risks of mixing dr-..:tgs in pal'enteral infusion. Neither cl.o 
they have the understar"ding bf the somewhat scanty informa-
tion that is available from manufacturers about the behavior 
or loss of activity which may follow injection of substances 
into various intravenous solutions (22). ~·he sparse data 
published on stability of drugs in in·t;ravenous solutions 
have appeared almost solely in pharmaceuti.cal journals, 
rarely read by doctors or nurses. One must appreciate that 
they have not kept abreast of all the problems and risks 
i.nvolved in adding one or more drugs to an infusion fluid. 
This should be the responsibility of the. pharmacist ;~ho. 
-~------~-----~----~---------
must assmafl this compounding function.. 
As might not have been the case a few years ago 
\~hen the nurse interpreted the physician's orders and~ 
then pr·oceeded to add whatever med.ications were called 
10 
for into the I.V. bottle, today's orders are being reviewed 
more closely for incompatibility and instability before 
admixture by the pharmacist. In order to perform an intra-· 
venous additive service .from the stanclpoint of safety~a=~n~d~-----
<Jconomy, the pharmacist must have reliable incompatibility 
literature available. It is of interest to note that, 
according to Peritore (23), since the implementation of 
their centra.lizecl intravenous add.itive program at their 
hospital, an avt~rage of tl":u:ee intTb.venous" incompatibilities 
or unstable mixtures have been avoided each week. 
As has been alludeo. to before, many investigators 
in the past have tried to classify intravenous incompati-
bilities into various categories \vith such labels as 
"therapeutic," "physical," and "chemical." While these 
classifications are of use, the real emphasis in the 
literature should be on whether, in the end, the d.esired 
therapeutic response will be altered:. The line, if there 
is one, dividing physical and chemical incompatibilities is 
often very narrow. A physical incompatibility is simply a 
chemical incompatibility that can be seen vrith the naked 
eye. Originally, physical incompatibilities implied to 
those in vrhich the physical properties of the ingr-edients 
produced a miA"ture that was unacceptable in appearance only. 
----~-------------~---~-~ ---
The overall objective, again, should. be to clecide whether 
the therapeutic effect of the drugs involved is altered 
and whether the safety and purity of the intravenous modi··· 
cation is retained following the mixing of the drugs. 
Academic categorization is of interest, but the physician 
wants to knov1 if the combination is safe and. still clini-· 
cally effective. 
One approach to the problem of intl~avenous incom-· 
patibilities in parenteral aclmixture might be simply to 
discourage the mixing of drugs so as to avoid~ the problem .. 
\~hilo this may be a valid concept, it is not a realistic 
approach and. has not been routinely accepted in the prac·· 
tice of r;wCL:Lcine. It is an unfort'.H.tate fact that an ill 
pei·son does not alvmys have only a single symptom which 
can be tre~rl:ed \'lith a single drug. Often there are other 
factors that complicate the situation. Therefore, it is 
not surprising that the physician will often attempt to 
11 
mix two or more a.rugs in order to more effectively control 
the several symptoms with which the patien'.; presents. In 
certain case.s, the patient's condition may require that the 
total amount of fluids be limited (2lJ.), or the physician 
may not want to inconvenience the patient with another 
venipu!leture (25). Under these circumstances, the drugs 
must be arlininistered to the patient within the volume of 
solution available for use. Still, in other cases, for 
the required a~rugs to be aclrninistered, they must be mixed 
for sake of convenience and practicality. Extemporaneous 
I 
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mixtures of drugs will invariably bring 1o1i.th them the rislc 
of drug incompatibility. 
That drugs are indeed add.ed to intravenous solutions 
in various combinations is a reality; polypharmacy is still 
widely practiced. One need only visit a surgical or meclieal 
ward of a hospital to discover this. 'L'he literature is 
replete; 1o~ith numerous surveys taken by pharmacistfl in order 
to determine the e:;.'tent that d.rugs and. combinatiSJns_o_f_dT_ng~~"----
are added to parenteral solutions in certain hospitals. 
'L'ables I and II summarize a fev; of the studies that have 
been done in recent years. Table I indicates the percentage 
distribution of I. V .•s ordered with drug additives according 
to the number of additives. '-[•able II demonstrates the fre-
queney of dist:ributi __ on of ctrug ingredients added to all I. V. 
solutionS~~" 
A three months analysis of intravenous admixture 
orders in a teaching hospital revealed that there were, on 
an average, 1.15 additives per infusion bottle (38). In 
the study performed by Holysko and Havin (26), it i'las found_ 
that an average solution for administration vrould contain 
1.9 drug additives. 
A booklet entitled, "I.V. Additives: Steps to Safety" 
(39), .prepared to serve as a guide for those either starting 
o:::· wanting to improve an existing intravenous additive pro-
gram, includ.es the following interesting statistics: 
1. Sixty-three (63) million I. V. prescriptions 
are administered in the United States each year. 
"""= D'tr7W""'"""'""-T"'"n"-
'l'ABJ:,E I 
Frequency of Additives Includ·~d 
(Percentage Breakdown Includes Only '!'bmo:e 
in Intravenous Soilutions 
I.V~'s Which Cont;lined Additives) 
Study 
Holysko & Ravin (26) 
Ho & Rosero (27) 
r1eisler & Skolout (28) 
Patterson & Nordstrom (29) 
Pang (30) 
Reii'man (31) 
Petruconis & Newman (32) 
Petruconis & Nevnnan (32) 
Average 
*I.V.'s '\'lith additives only. 
Year 
1965 
1965 
1966 
1968 
1970 
1971 
? 
? 
J~To~ of' 
r.v<&~s 
(138)* 
1~172 
701 
1,552 
226 (llJ-1)* 
(890)* 
l 2 3 I % of Solutions 
48 30 19 
30 24 lL~ 
58 27 9 
40 24 12 
76 19 3 
75 20 5 
58 38 4 
t:;L• 
/T 24 12 
521 26 10 
4+ 
3 
32 
6 
11 
2 
0 
9 
9 
!-' 
\.}~ 
! 
TABI.:E II 
Frequency of Additives Includ3d in Intravenous Sol1utions 
(Percentage BreakcLown Includes Number of Additives in All II. V. 's Surveyed) 
Iio. of 1 or 
Study Year I.V.'s l'1ore L:_ 2 ::>: 4-+ / 
% I 96 of Solutions 
-
Holysko & Ravin (26) 1965 4-5 
Ho & Rasero (27) 1965 138 70 
Meisler & Skolout (28) 1966 "''"' _.N 
Goodwin (33) 1966 57 
Carlin & Perkins (34) 1968 7l6 65 I ll....-.<:) 14 4 l 
Patterson & Nordstrom (29) 1968 1,172 86 
Jacobs & Superstine (35) 1970 500 60* 
Pang (30) 1970 701 60 
Francke & St. Clair (36). 1971 74- 50 14- 1+ ~ 7 
Reifman (31) 1971 1,552 51 
Catania (37) 1972 1,202 45 I 33 7 6 
Petruconis & Newman (32) ? 226 62 
Average 60 
--
*Sixty percent contained two· or more additives. t-~ .;:-
ll"i .: II": .11:::-~111 ; I 1, 
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2. Of these, 25 million I.V,e prescriptions contain 
one or more additives. 
3. The probability is that 1 out of 50 persons in 
the Unit eel States will receive an I. V. admixture in a hos-
pi tal. 
For the future, Dorm ano. his colleas"lles (lw) believe 
that intravenous aCL"!J.ixtures containing more than one d:eug 
adeditive will be a technique of the nast in the next few 
years.e HO'dever, a habit of many decades cannot be broken 
overnight., He suggests that the percentage of adm:i.A.'tures 
containing only one adclitive has increased from approximately 
50 percent to over 80 percent, although no substantiation is 
offered.. He believes this to be a result . of the education 
of __ the m0dic.ol Hi~~1ff to the problems associated 1.·1ith intra··-, 
venous admixi;uros. He speculates thai; "mini-bottles" con-
taining one additive might be manufaci;urea. to provide "pulse 
therapy" via an intravenous Y setup to eliminate all admix-
tures containing a multiplieity of drugs. 
It is very apparent from these few examples that 
the use of multi-component admixtures in various American 
hospitals is.very prevalent. 
Because work in.parenteral incompatibilities has 
frequently beeri done on a "piece-meal" basis rather than 
on i;he basis of scientific deliberation, data have accumu-
lated slowly. Early methods of incompatibility studies, as 
mentioned before, were often crudely accomplished in that 
judgments were made on the basis of visual observation. It 
----------------
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is also evi<.".ent that the earlier methods were often hardly 
scientific in that the;y often lacked vital information such 
as drug concentration, type of parenteral fluid used, order 
of mixing, storage conditions, the volume of the vehicle 
used, etc. 
There is a lack of uniformity in the me-thod.s that 
have been ur;ed. to cletect incompatibilit3' and different 
methods have relied upon d.ifferent guidelines for detection 
Often the methods were somewhat unrealistic and. did not 
simulate actual clinical practice. 
Frequently, authors would attempt to recommend 
procedures to eliminate the problems that might arise. In 
o:cd.er to rr-Jsolve the problem of a precipitate~ they might 
euggest either to mix the admixture well or to change the 
order of mixing. While this may eliminate or d.elay imme-· 
diate formation of a precipitate, it is unlikely that the 
ingredients wiil be protected from chemical degradation. 
1\n example of this is the report by Jones (41) 1~ho statea. 
that Solu-Cortefa was compatible 11ith Nembutal Sodiumb 
based on ph;y-sical (visual) results. Hovrever, on the basis 
of the results of Anderson (42), this combination should be 
predicted to be incompatible (chemically) due to the high 
pH of the combination resulting from the alkaHnity of the 
Nembutal Sodium. 
a - l'lerck Sharp & Dohme, West Point, Pa. 
b - Abbott; Laboratories, North Chicago, Ill. 
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In addition to these weaknesses, ~1eyers (LI-3) also 
adds the follOI·ling points: 
1. Jllany formulas actually tested ha-ve subsequently· 
been altered. 
2. I1any combinations tested in .advance by pha.rma-
ceutical manufacturers have ne-ver been presc.ribed and., more 
· important, should never be pre:3cribed .• 
most part, superficial in nature. 
Donn (L>O) expressed his d.iscontent with the a-vail·-
able information on intravenous incompatibilities, par-' 
ticularly the charts. His reasons Nere the follow·ing: 
1. Conr~lusionro are usually ba.sed. on those ad.diti ves 
in c;ases be 
:o):J.emic.ally ·;;;he same as the a(lditive stocked. by a particular 
hospital. 
2. The solutions utilized may not in all cases be 
chemically the same as the solution utilized. 
3. The criteria utilizedin making a decision as 
to the compatibility of intravenous admixtures are not 
standard.ized. 
4. Combinations are usually limited to two drug 
additives in a single I. V. solution. 
5. Frequent conflicts between references exist 
listing identical combinations. 
6. Data obtained. from studies are often scientifi-
cally questionable. 
7. 'J:he information is usually inadequate in that 
not all of the additives used in a particular hospital are 
.listed. 
To deal with the problems of possible drug inter-
actions that may arise with the use of multi-drug admixtures 
in infusion fluids, many pharmacists and other workers have 
attempted to concluct various types of compatibility studies. 
list of references on intravenous ad.elitives covering the 
years from 1955 to 19?1 (lJ.l.J.). It is quite apparent from 
their list of 133 references that there has indeed been a 
great deal of activity in this area. ~'hese studies may 
have utilized the very simple procedure of ad.diting two or 
rather the visible, results that might occur as determined 
by the presence of a precipitate, color change, evolution 
of a gas, or the presence of a haze or cloudiness. At the 
other end of the spectrum, procedures involving extraction 
or chemical alteration and manipulation of the drug after 
admixture and subsequently biological and chemical testi~g 
have been employed to determine its potency and structural 
integri.ty. 
One of the earliest studies conducted was that by 
Bogash (45) in 1955. After admixture of specific parenteral 
products to commonly used solutions designed for intravenous 
injection, the soluti.ons '-'/ere inspected immedi.ately and after 
four hours. He based compatibility on the absence of 
19 
particulate matter in the solutions and later compiled one 
of the first compatibility charts on the basis of his work. 
Bogash stressed that it \vas di.fficult to appraise whether 
several parenteral drugs were compatible upon admixture. 
It appears thfX~ he also exhibited a keen insight into the 
problem by observing that the constituents of the various 
solutions have become complex anJ.~ in many <~e.fles 9 the neces-
In 1961, Kirkland and his associates (11-6) conducted 
a similar study. Their work remains tode.y as one of the 
most e:x:tensive of all tests carried out representing more 
than 8,000 tests using 137 drugs singularly or in combina-
t:i.on with GO Abbo-Iii.tera parenteral solutions. The results 
over 
21v hours, were compiled into a comprehensive and complex 
compatibility chart. They realized that due to the multi-
plicity of ingredients there are many other reactions, 
whether visibly detectable or not, which may occur ~1hen 
parenteral medications are combined. 
Riffkin (4?) warned that extemporaneous mixing of 
drugs invariably brings the risk of drug incompatibility. 
He furthel' noted that any changes in pH, viscosity~ tonicity, 
or particle size distribution could easily upset delicate 
systems. In addition, modifications of oxidation or reduc-
tion conditions, light exposure, or storage temperature 
a - Abbott Laboratories, North Chicago, Ill. 
'i 
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:requ:l..rel:H-mt:.s could result in a loss o.f activity. 
I,c_rt;er, Dunworth and. Kenna (16) stated that very 
little, information was available depicting the incompati-
bilit:Le~' of tHo mectications in intravenous Bolut::Lons and 
ev(::n 1es'3 inf•.):I~nla.t:Lon had. been publishec1 :Lnd:Leating the 
bilit;y of med.icamen:tf::1 in i.nt;:.raveno11s solutions(> 
In the same year, Hisgen (17) announced. the x·e:~.su.lts 
of his ::1tud~v which 1.'iere aecomplished by ao.d.ing one ml. 
aliquot of :r.•econstitui:EJd additives to five mls. of sterile 
d:l. st:l.lle)d Vi'D.i:E-n' in pa:b.•s, ~~he a.d.mixtures were then obnerved 
for signs of pm:t:Lculat:e matter. In this study, 3Lf. arugg 
int;ended. fox~ intrav(:;nous UE;e wer.e eross ...... mf:ttched to test: for 
His commen-t; that 1. 
". , ,, it might be safe to assume that if 
tbe drugs vmr•~ incompatible at high concentra-
tiorw, ~~ similar phenomenon might be expected 
to occur in more dilute solutions in a high 
percentage of the situations," · 
may be open to question. 
In 1966, Im and IJ<ltiolais (1+8) :r:·eported on the 
results of their vTork which investigated the ph;y·sico-chemical 
compatibility of admixtures of penicillins and tetracyclines 
in 5 percent Dextrose Injection. Their method to detect drug 
interactions was based on degradation evidenced by spectro-
photometric analysis of the individual arugs. A loss in 
absorbance at the vmvelength of maximum absorption formed 
a basis for adjudging the mixture incompatible. 
Patel and Phillips (49) used the microscope in an 
a.ttempt to develop another method for studying physical 
compatibility of intravenou~' a.rug admixtures. The pub-
lished results also lacked many of the specifics and 
C~l 
d.etails :Ln terms of method.s and techniques needed for 
prope.r1y understanding and interpreting their compatibility 
chart. ~'he stully was conducted simply by examining the 
admixture with a microscope for visible evidence of a pre-
-
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In 1967,. Gallelli (50), at the National Inshtutes 
of Health~ conducted stabilit:y studies of six different 
dx'Ugs \'lhen added individually to intravenous infusion. fluids. 
His stud;y was limited. to single component admixtures of the 
.rl1:ugs to his :L:afusion flu:i.J .. s of Sodi.uJn Chloride In;jection 
. i .and. ;~ percent DeJ:trose In;jection., His method.o of a:J::::ay of 
the drugs, at time intervals of over a period of' one to 
four weeks, included either spectrophotometric or micro-
biological assay. This study is the only one published in 
the literature which involved the stability and duration of 
activity of anticancer dxugs. The two oncolytic agents that 
he worked wi.th were mercaptopurine sodium and cyclophospha-
roicle. Gallelli compare(l his results to the statement;s found 
in the ma.nu:facturer' s product information concerning the 
administration and stability of the drugs in intravenous 
solutions and found that in many cases the drugs \~ere 
stable for much longer periods of time than had been recom-
During the same year, Parker (51), acting on behalf 
of Abbott Laboratories in continuing the work of Kirkland, 
reported on a chemical compatibility stud.y that involved 
eight drug products in commonly used intravenous fluids. 
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Using pH readings and chemical or biological assc1ys, he 
presented one of the first examples of chemical incompati-
bilities which did. not produce visual changes in admixture. 
Parker emphasized the important role pH plays .in ·i;he sta-
-----b,il-i-t;JL--Of--<"~J:'Ug-Wb£'.nc_diluted to a large volume by a 
solution of a d.ifferent; pH. These solutions may contain 
dissolved. atmospheric oxygen which might catalyze or 
initiate chemical reaction and. cause decomposition of the 
drug. Unfortunately, with this study, which is also true 
of later publi0ations of Parl:er, experimental method.s and 
procedures \Jere not stated. 
Iie_thods of I'redictinp; Intravenous IncoJ!!patibilities 
The results of the experiments reviewed thus far 
were, for the most part, the results of actual experimen-
tation anC'. work with intravenous drug admixtures. In more 
recent years a number of authors have attempted to predict 
the pharmaceutical incompatibilities of parenteral medica-
tions which might occur. As ~<Till be sho1m, most of these 
predictions have been based on an alteration of pH when a 
drug is added to a vehicle of different pH. One of the 
earliest articles written concerning the prediction of 
intravenous compatibilities was that ~rritten by Edward (53). 
In her study, Edward determined the pH change in an intravenous 
-
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vehicle 1~hen a drug, or combination of drugs we.re added. 
This information was then compared. with the known pH 
stability range of each drug. The results of this com-
parison could then be used to predict the possible acid-
base stability o:f drug or drug combinations in a vehicle. 
Carlin cmd. Perkins (34-) • on the b1wis of a survey 
2 z / 
of patient charts at a local hospital, reviewed the poten·-
jaJ inter-reactions of the penicillins and other drugs. 
By using available data from chemical incompatibility· 
studies, a method was demonstrated. for estimating the 
reaction rate of certain additives by calculating the time 
required for 10 percent of the drug to react. 
Later, Webb (53) attempted. to show a relationship 
of incompatibility to :pH by reArraJlging the comratib:i.lity 
chart comp:Lled by Patel and Phillips so that .the arlditives 
were listed in terms of increasing pH, and. were at right 
angles to the same additives listed in terms of decreasing 
pH. On the basis of this chart, it was Webb's contention 
that ilTt;ravenous incompatibilities could be predicted due 
to the fact that the solutions v1ith extreme pH values are 
incompatible with solutions with pH values of the opposite 
e:A.-tremi ty. 
More recently, Eo and co-workers (54-,55,56), in a 
series of articles, have attempted to demonstrate how to 
p1•edict the pharmaceutical stability of parenteral solutions 
from the point of view of kinetics and particularly rate 
constants. While Eo explains that the "elementary" 
-
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mathematics used in his articles should present no problem 
to the present day pharmacist with an undergraduate training 
in physical pharmacy, it is this author's opinion that he 
does exceed the imme<liate comprehension level and point of 
practicality needed to reach the average hospital pharma·· 
cist. 1!Jhile Ho' s ,work is probabl;y beyond the mathr;,matical 
ability of the average hospital pharmacist:, he does make a 
on intravenous incompatibilities. Such literature is pre-
sented in a manner that is not sufficiently comprehensive 
to relate the various situations such as pH, temperature, 
and vehicle. He explains his reasoning in the following: 
"Firs!:;, it toJces time, effort, initiative, 
ano. reasonable scientific ability for a research·· 
o.r:Leni;~c1 hc:3pit;al pharmacist to find. a T·eliB_ble 
an~;.lytic~.:t1 method and then to study· the kinet~.0s 
oi" decowposit;ion of the drug under· varying condi-
tions. Secondly, the presentation of t:he data in 
a manner that can be understood and utilized by 
others to whom the study is intended may vary." 
His papers attempt to help the professional pharmacist con-
solidate and interpret the current literature on the stability 
of clinically significant parenteral admixtures. 
Recent Studies of Intravenous Admixtures 
\vork in the more recent years, in the area of intra-
venous incompatibilities has been some~1hat of a different 
nature than the earlier studies. Earlier work concerned 
itself basically with the nature of physical incompatibili-
ties and for the most part tolas conducted on the basis of a 
survey of drugs in general and drug classes. Detailed 
-
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involvement; concel'ning :ind.ividual incompatibilities was 
usually not attempted. The major emphasis \'las on cover-
ing a broad spectrum of d:rugs on a someiiThat superficial 
basis, skimming the surface of the problem as it were,, 
contrast to this, the nwre recent studies have mostly 
In 
limited themselves to the incompatibilities of one or two 
drugs in combination with a fe\·J other drugs. The ncnver 
_____ _:;f'u,tJllili_e_$ have been more detailed in :eelatinp; teclmigueG and 
have attemptecl to d.iscuss the individual reactions that 
might occur between drugs and the effect of these reactions 
on the ef.f'icacy and_ safety of the mixture. Attempt has 
been madey where possible, to examine the therapeutic integ-
r·ity of a ch•ug !J.fter it has been put in combination ~1ith 
The) reDearch conducted by Simberkoff, _!'!t. a~. (57) • 
is of particular interest because.it is one of the only 
studies on the stability of drugs in infusion fluids con-
ducted by physicians. In this study, the inactivation of 
different penicillins by carbohydrate solutions at alkaline 
pH presented a new concept of incompatibility. It is their 
finding that when penicillins are added to solutions of 5 
percent Dextrose Injection, rendered to an alkaline pH, it 
is the carbohydrate :fraction of the solution that promotes 
the breakdown of the penicillin moiety. They hypothesized 
that penicilloyl esters of the carbohydrates are formed 
initially. These then undergo hydrolysis under the condi-
tions of the reaction mixture. 
-
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.Another study involved the parerrberal compatibility 
of aclmi::c-tures containing metaraminol bitartrate and hydro-
cortisone sodium succinate alone and in nine oombinat:ions of !'= 
various concentrations and. at various pH values in 5 percent 
Dextrose Injection. That investigation includecl a complex 
assay procedure involving pH ad.justments and extractions 
with chloroform with a final.analyds using either an ultra-
------'>Yuiuov1£t OJ' inf.T•c:tred nJlac~phot;ometer (58.,__._. _____________ _ 
In a study rJf the stability of ampicillin and car-
benecilJ.in in C01Th1lOnly used. infusion solutions • J'acobs and 
co--workers (59) determined the potency of these anb .. bioti.cs 
using a microbiological arosay at different time intervals 
over a per5. orl of 2l~ hou:r·s c. 
Zost' end. Yo.nchick (60) clctormined the compatib:i.J.i.ty 
and sta.bility of O.isodinm carbenicillin in three commereial 
infusion solutions and in combinations vTith six other drugs. 
Carbenicillin was assayed microbiologically by the use of a 
cylinder plate assay using a strain of the organism 
Pseudomonas. They found that carbenicillin is quite stable 
when added with other ingredients. It is of particular 
interest that in their study they found there \•Jas no corre-
lation bet1~een changes in pH and changes in microbiological 
activity. 
Riley (61) reported on a study on the visible effects 
of intravenous d.rugs added t.ogether in two standard intra-
venous fluid.s. This study very closely paralleled earlier 
studies d.one in the United States, that of Kirkland (12) 
2'? 
done ten years earlier. 
Using an old principle and applying it in a novel 
manner ~rith an innovative technique, Catania anc1 King (62) 
presented their results o.f studying the physic:al and chemi·-
cal compatibility of sodium ethacrynate 1vhen combined 
individually with eight cardiovascular and psychotherapeutic 
agents in Sodium Chloride Injection. Their a.daptation 
involved. the use of a spectrophotometer along::---J'li1L__h_pJ1~-------
measurements to analyze the compatibility o.f' the aclmiztures. 
They also .found little correlation between the pH values 
of the admixtures and. the nonvisual chemical reactions 
detected in their study. 
0\rw:· the past three yea.rs, in a continuing series 
oi.:C -articles~ Parker· (63) has attempted. to relate the results 
o.f'; his continued work in the area of intravenous incompati-
bil:i.ties in Journal's department entitled, "Compatibility 
Digest." These are concerned v1ith the compatibility of one 
particular drug in combination with other additives. The 
results are usually broken o.O\-r.a into three tables: 
1. Physical compatibility of the drug with other 
additives in I.V. admixtures; 
2. Stability of the drug in various I. V. fluids; 
and 
3. Stability of drug in dextrose 5 percent at 
variou.s pH values. 
It is unf'orttmate that the method or technique of drug 
assay is not well described. 
28 
As can be seen, much \~ork has been done in the area 
of intravenous incompatibilities. Unfortunately, very fevr 
of the method.s employed in the various studies have been 
stand.ardized and often the results may not be entirely 
reliable. It has often been saio. thai; misinformation is 
worse than no information; however, because of the desperate 
need. for suc;h material, stw:hes must be continued so that 
more and more informatioi:r \'lill be available to the practi.c-i.ng· 
pharmacist and nurse who must then weigh and evaluate the 
studies as to accuracy and relevancy. 
In an atterq)t -to consolida.te the many charts avail-
able and the nurn8rous published and unpublished reports in 
the lit;e:r.:·c.t1Jre into a co;::tcise and usable form, King (64) 
har; compiled a "Guide to Parenteral Ad.miA.'"tures." This 
represents the first successful attempt to centralize avail·· 
able data and to establish a mechanism for dissemination of 
updated material. 
OncolY!_ic Drug Admixtures in Intravenous Chemotherapy 
The term cancer includes a group of neoplastic 
diseases ~1hich occur in all races of man and species of 
animals. It is, in essence, a disease of cells characterized 
by a reduction. or loss of' effectiveness of the normal cellu-
lar control and maturation mechanisms which regulate multi-
plication and other functions required for homeostasis in a 
complex multicellular organism (65). In the United States, 
cancer rates second to heart disease as the major nause of 
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death, with over 300,000 fatalities a year. Under current 
treatment methods, only one-third of the patients are cured 
by surgery or radiation therapy. For the most part, chemo-
therapeutic agents have been employed toward the palliation 
of symptoms, management of complications, and prolongation 
of life (65). It should be emphe.sized that while chemo-· 
therapeutic cures are currently attained. only in relatively 
rare tumors (e.~ chori ocarcitlnma_anil_Burki±J;-'-.s--l-iJ111Pb.m-l-;,--------
drug research may provide the ultime.te cure for cancer. 
The future treatment and control of cancer will probably 
reside in the c-hemical approach, based upon a complete com--
prehension of the carcinogenic process (66). 
As the incidence of cancer in the United States 
cpntinues to i11crease, so d.oes the use of those drugs u.sed_ 
in the treatment of the disease. Since World War II, the 
number of anticancer drugs has increased tremendously. 
Unquestionably, the last 25 years have witnessed greater 
advances in this field than during any previous period (66). 
Experimentation continues \·lith the use of cytotoxic 
drugs. 1-Jith the advent of the testing of new oncolytic 
agents and the new uses of older drugs, the field of cancer 
chemotherapy has become a very complex specialty. It is of 
interest to note that at the United States Chemotherapy 
National Service Center, approximately 30,000 substances 
are annually screened for anticancer activity (67). The 
parenteral use of anticancer agents, whether it be by the 
traditional intravenous route, or by less commonly employed 
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routes such as intraarticular or intrathecal, plays a large 
part in the use of these drugs (67). This is apparently so 
because many of the drugs are either not effective orally, 
or adequate blood levels cannot be achieved by the oral 
route. Also it may be that "!;he specific site or target 
cannot be hit adequately without causing undue toxicity to 
the rest of' the body. This may be the case in regional 
theraJlY and in intraa rt er-1 aL_i]1fJJ_&c-Lon~62L)-.-------------:------~== 
I 
In some circumstances, attempts have been made to 
improve the effectiveness o.f chemotherapy ~rithout excessive 
increase in toxicity, utilizing drugs in combination or 
sequentially (69). In treating the various types of can-
cers, the term combination chemotherapy implies that a 
given course of therapy consists of seve:('al o.rue;s, chasen 
to exhibit varying mechanisms of' action and varying mani-
festations of toxicity. These are administered according 
to a schedule devised empirically. This is an attempt to 
arrest as many neoplastic cells as possible in the dividing 
(drug-susceptible) stage, or to expose those cells to maxi~ 
mal toxic effects, but to limit or spread the side effects 
and toxicities of each drug to the patient over several 
organ systems (70). 
Combination therapy is often employea_ and is of 
greatest value in tumors which grmv rapidly and which pro-
duce resistant strains rapidly (71). In the treatment of 
leukemia, where the final objective is eradication of the 
disease, combinations of drugs have been used frequently 
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in an attempt to eliminate more of the J.eukemic ceJ.ls. 
Although most of these proced.ures are still investigational, 
encouraging results have been obtained from multidrug regi-
mens in which patients are treated 11ith combination regimens 
variously kn01m as VARP, BIKE, or P0!1P treatments. The 
combinations of treatment consist of courc:es of vincristine, 
methotrc~:x:ate, mercaptopurine, prednisone, and cyclophos·· 
l------j>i-l-a-m±d-e--6~'\7\.~"f.r-a-t-"------r-eg"a-l-atc:u'-±rrtTn}Vai-s--mrt-±i------a-----:remiss"I.;-· o"1"l---.;-i"'s _____ _ 
obtained. In these treatments~ because each drug is given 
in full doses, the possibility of toxic reactions is 
enhanced (68). Also, recently, combinations of drugs are 
provinr~ to be more effective than single agents in inducing 
more complete remissions and longer durations of disease-
free :r··em~-~s:r.on in such caJ!.cers as chorioca:eeinomav Hodgkin.' .s 
clisease, acute lymphoblastic leukemia in children, reticulum 
cell sarcoma, and teratoma of the testis (72). 
\Vith the increased parenteral use of anticancer 
drugs, particularly those that are given intravenously as 
an infusion over a period of time, much concern has been 
generated about the stability and compatibility of these 
drugs in intravenous fluids, alone, and more particularly in 
combination with other anticancer or non-anticancer drugs. 
In most teaching hospitals and government cancer 
institutions, the actual physical combining of anticancer 
drugs is d.iscouraged. For an example, at two branches of 
the National Institutes of Health (the Clinical Center in 
Bethesda and the National Cancer Institute in Baltimore, 
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Haryland ) 9 the combining of anticancer drugs, as well as 
the combining of almost all drugs in intravenous mixtures 
is avoided. The principle reason for this is to avoid any 
possible chance for an in·t;eraction to occur that might 
alter the effect of their experimental drugs. Q' olnce 
these hospitals are basically research institutions, 
experimenting with nev1 concepts and drug treatments~ they 
enhancing, decreasing, or nullifying the effect of the 
drug being studied (73). Another fact considered., ·~· speclJ.J..--
cally in regard to the anticancer drugs,. is that most of 
these chemothers.peutic agents e:x:J1ibit a very low ratio o:f 
therapeutic to t;oxic activity, and altera.tion of the drug 
in any way may seriously alter this delic:ate t'l'lt:i.o e.n<'l. 
affect the outcome of the treatment. Doses of most of the 
oncolytic agents approach the limits of normal cell tolerance 
by design, so that maximal kill or inhibition of neoplastic 
cells occurs and. the chance of survival of neoplas-tic pre-
cursors of the original tumorand any metastasis is mini-
mized (70). Since each antineoplastic agent must be used 
in the optimal schedule, route, and dosage for the par-
ticular indication, any alteration in the agent could 
seriously decrease its effectiveness or cause serious toxi-
citiesand even death (68). 
That oncolytic drugs are given in combinations and 
\~ith other drugs in parenteral solutions appears to be a 
very prevalent fact, although probably not to the extent 
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as it is with other admixture combinations. In reviev1ing 
three of the main journals that are exclusively d.evoted to 
the sub,ject of cancer, "Cancer," "Cancer Research," and 
"Cancer Chemotherapy," it is quite evident that comb:Lmrt;ion 
intravenous therapy is :indeed use<L H01•1ever, little infor-
mation could be found regarding the compatibility of' chemo-
therapeutic agents alone or in combination in infusion 
fluid-S. As mentioned be:l'ore, GaLlaD..:i._(:;.D_)_st.udieLt:.hc'--------
compatibility of mercaptopurine and cyclophosphamide alone 
in infusion fluids, but no attempt was made to determine 
the compatibility of the admixture of these two or other 
anticaneer agents. Correspondence with selected companies 
requesting information on the intravenous admixture eompati-
bilii;ies of their oncolytic drugs, y:ie1ded the response that 
such information was not available. The only information 
that could be located on this subject was found in the book-
let of compatibility tables of drugs in infusion fluids 
compiled by the Pharmacy Department at the National 
Institutes of Health (74). That compatibility data, ho\v-
ever, is not documented and contains no references. For 
most of the anticancer drugs included in that booklet, a 
statement is made to the effect that, "It is recommended 
that no other drug by physically combined with this drug 
in the same infusion bottle because of lack of compatibility 
data." Thus it is quite apparent that essentially no work 
has been done in this area of intravenous incompatibilities. 
It has been mentioned before that because of the 
pharmacist's training and knowledge of chemicals and <lrugs, 
pH concepts, buffer systems, etc~, he may, in many instances, 
predict potential "physical" and chemical, as well as thera--
peutic, intravenous incompatibilities. Howeve:r:•, in other 
instances t;he pharmacist's logical predictions ~!ill not 
hold true and he must rely on the specific work of others, 
if such :i.s available, in order to justify an admixture in 
terms of efficacy and safet;)'. Invasi:iga_t_i_cmal _ __.c::rJld.if>~,__ _____ _ 
covering the physical and chemical compatibility of intra-
venous admixtures of chemotherapeutic agents • carried. out 
on a scientific basis~ is definitely needed. It is because 
of this that a study into the intravenous stability and 
compatibilH;y of st~lected anticancer admixtures vms initiated. 
It is perfeetly clear that there is no sho:M; cut to taking · 
the actual drugs themselves and mixing them Hith the infusion 
fluids and then analyzing the products to determine the effect 
on the components. 
Because of the lack of information relating to the 
compatibility of antineoplastic agents, it is important to 
examine these as they might be prescribed for intravenous 
administration under clinical conditions. This study 1vil1 
include delineation of the physical and chemical compati-
bility characteristics of a group of agents \vhich may be 
a<lministered in intravenous admixture. Limitations in the 
selection of the specific drugs were imposed by the usual 
route of administration and availability of products. 
Investigational drugs were not considered in this work. 
~ 
li 
; 
ii 
I 
! 
I 
I 
I: 
I 
.I 
35 
~:he four oncolytic agents to be examined include: 
5-.fluoronracil, methotrexate sodium, cytarabine, and 
vincristine sulfate" Because, on occasion, soclium 
cephalothin or prednisolone sodium phosphate may also 
-
~-
be admixed with these, it seemetl appropriate to include 
these as part of this stud.y" Evaluation of admixture 
compatibility v1ill utilize both visual and spectrophoto-
me·t;ric roceclures. 
CIIAJYmR II 
1./CPERH'iENTAI, PROCEDURE 
The purpose of this study vms to determine the 
pty,,;:i.ce.l ana. chemic;al eompatibi.Li.ty as well as stability 
:t:'oid d:eugs in an intravenous infuroion fluid. :Five percent 
Dr"xb:o6e Injection 1vas Belec-ted as the vehicle because 
of its wide u.sage in medicine for the purpose of admin-
It vms v6.thin the purposes of this stud.y 
to ::d.mu.Ie:te actual clinical practice as much as possible 
to ;(tC"'v~idc r·csuJ.ts o.s rcs.listic and n-.:eaningful as possi-
ble. 
Physical compat-ibility v1as a.e-termined by visual 
observation of the admixi;ure as might be manifested by 
the presence of a precipitate, color change, gas evolution, 
or by the presence of a haze or cloudiness in the solution. 
Chemical compatibility was determined through the use of 
speetrophotoroetric analysis, according to the method 
developed. by Catania and King (62). 
:.!.'he drugs chosen for this study included: 
5-··fluorouracil (Fluorouracil)a, sodium methotrexate 
a - Roche Laboratories, Division of Hoffmann Ia Roche, 
Nutley, N. J. 
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3? 
(l>lethotrexate)a, cy!;a:r-abinc (Cy!;osar)b, vincristine sulfate 
'•' · ·)e d · J a· h h t (' d l)d \. vneov:tn ~ pre m .. so .. one so J.um p osp a ·e ,1y .el traso , 
an.d soclium cepbalol::hin (Keflin) 0 • 
p·.2e] .. iminary __ Stud:y: 
A Ba.u::1ch and Lomb Spectronic GOO Double Beam 
., 
Suectro1Jhot;omt~ter" was used to obtain t;11e ultraviolet •.. .... 
absorbance spectJ.:um of each of the drugs used in. the study, 
uncombined. and in the admixtures. The (leuterium lamp of 
the spectrophotometer provided an electromagnetic incid.ent 
beam in wavelength range of 220 to 350 millimicrons .fo~~ thr~ 
analyt:LcaJ.. absorption spectrophotometry. 'I'he soJ..ut:Lonn 
were analyzed in Bausch and Lomb 33-27-25 Silica Ouvettes 
and a Id.nc~ar/I.Dg Varicord '~? Recorderf was used to obtain 
a. rscordin.t-; of tho spectra. 
The dextrose injectiong used in this experiment ~~as 
transfo:rred throughout the experiment by means of an intra-
vencms injection set. 11 
-----·------
a -· IJed.erle Laboratories Division, American Cyanamid Company, 
Pearl River, N. Y. 
1:J The Upjohn Company, Kalamazoo, !1ich. 
c Eli Lilly and Company, Indianapolis, Ind. 
d- l'lerck Sharp & Dohme, Division of l'Terck & Co., Inc., 
\vest .Point, Pa. 
e Bausch and IJomb Optical Co., Rochester, N. Y. 
f Photovolt Coi.'P•, New York, N. Y. 
g Cutter J::aboratories, Berkeley, Calif. 
h Saft:i.set; #860-35, Cutter I,aboratories, Berkeley, Calif. 
~ 
~ 
I 
I 
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In order to red.uee any chance of error and. to 
insm:e accurac;y, before each spectrophotometric scanning 
or absorbance read.ing was clone the instrument was cali-
bratcJ<'i.~ Every attempt, however, was mad.e l;o stanchrd.:i.ze 
proced.m.'e and tec:.hnique throughout the experiment. 
plotted for ee.eh oi.' the 0J~U[5S: added separately to the 
preparing rcmdom dilutions of the drugs :i.n the dextrose 
solut;j_on until a concentration vms found where an abse:rp-
tion spectrum could be obtaineil.. Dilutions were prepared 
to achieve maximum absorbance in the range of 0.2 to 0.9. 
In thege, :5 percent Dextrose Injection was used as the 
:r:efe:c-enee _solution~ These spectra v.rere taken to establish 
the reference .or stand.ard spectra for each of the drugs. 
Anal:z.sf!cs of Admixtures. 
J!'or an analysis of the drugs in admixture, the 
six drugs were added in pairs to the 5 percent dextrose 
solution. These were cross-matched so that every possible 
unique combination \qould be tested. It was realized that 
probai:>l3' not all combinations tested. have been used in 
clinical medicine; however, it was felt that since the 
area of cm1eer chemotherapy is continually changing, the 
possibility· still exists that all combinations might be 
used at some time or another. 
Haintaining a constant pattern for the order of 
i 
~ 
t 
r 
I 
I 
-I 
' 
mixing, the drugs were added to the solution of 5 percent 
Dextrose Injection. Thorough mixing was done after the 
addHion of each drug; the final admixtures being stored 
at room temperature .and with normal exposure to light. 
For the purposes of determining the presence of 
any "physical" incompatibilities, the admixtures were 
observed for visual changes (color change, evolution of 
admixture. 
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In order to determine tb.e possible prescnee of 
any chemical incompatibility~ the ultraviolet absorption 
spectrum for each drug Vlhile in combination vms <letermined 
to observe any change in absorption eharacterist:i.cs. The 
resulting spt::ct:t:um \lias t·hen compa:c·ecl to the standard spec-
trum v1hich had. been obtained both in the preliminary study 
and at the start of each admixture. Any changes in the 
spectrum of a drug might present as an alteration in the 
number or size of the absorption peaks or as an appreciable 
change in the wavelength of peak spectral absorbance cAmax) 
of the clrug. 
Since each combination admixture contained. tvw drugs 
in the 5 percent Dextrose Injection, in order to obtain a 
spectrum for one of the drugs present, everything in the 
combination, except the par~icular drug being examined 
would have to be blanked out. This was accomplished by 
making up two individual solutions each containing only 
one of the drugs in the pair. These \~ere then used as the 
reference solutions. 'l'here:fore, the composition of the 
reference solut;ion.s WJ.s identical to the admixture solu-
ti.ons except only one drug of the admi:xtu:r.e pair was 
present. By simply alternating the reference solutions, 
:indivi(lua.J. absorption spectra could be obtained for each 
drug in the adrnixture solution. Each admixture vms per-
formed in triplicate and absorption spectra ~;ere obtained 
:for each drug in the combinatiom> at 1, 4, and 8 hours 
after initial admixture. 
In order to simulate the actual conditions of 
admixture in the clinicr~l setting, all drug preparations 
were reconstituted., i.f 11r1cessary, according to the manu-
Lj.Q 
facturer' s recommend.ations. Appropriate quantities of the 
drugs were transferred to the infusion fluids with either 
graduated or volumetric pipets to 50 rnl. volumetric flasks. 
The concentrations of the drugs used in the admixtures were 
selected to resemble, as closely as possible, those used in 
actual elinical praetice. It was deeid.ed to use those con-
centrations that were consi<1ered, according to literature 
and the manufacturer's product information, normal doses 
for an average adult of 70 Kg. (154 lb.). The actual dosage 
of anticancer drugs employed frequently depends upon the 
particular type of cancer being treated. In this study, if 
this were the case for a particular drug, an at·i;ernpt was 
made to use a representative concentration of the drug. 
Where it was found that a wide dosage range existed, the 
concentration used. was that consia.ered most convenient for 
-
~--
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I 
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the spectrophotometric analysis. Since it was observed 
j_n the literature that most recommended doses were stated 
in terms of mg./Kg./d.ay, a total daily dose for a 70 Kg. 
patien:l; vras calcula:!;ed and divid.ed b;y three. ~'his amount, 
aclded. to 500 ml. of the infusion fluid, yielded. the con-
eentration at which the experimental admixtures were pre-
1)a::ed~ For experimental conveniences~ solu·t-;ions and 
ad.mixtures were p:eerw.re<l in SO ml. volumetrie flaslcs. 
Although all admixtures were made at therapeutic 
concentrations~ it 1vas occas:Lonall;)T necessary to dilute 
the arJ..mixture immediately before scanning, to bring it 
into the concentration range which could. be hand.led by the 
.spt:ctrophot ome"L: er. 
CHAPTEH III 
HESULTS 
In the following section, a number of graphs 
displaying the Beer Ie.w plots for each of the drugs, alone, 
in the 5 percent Dextrose Injection are resented (Gra hs 1 
through 6). These relate the absorbance at the )\max as a 
function of concentration. 
Figures 1 through 39 represent the results of the 
speetrophotometric analysis of each of the drugs, alone· a.nd 
j_n pairs as the admixtures. By comparing the spectrum of 
each drug alone with the spectrum obtained. of the drug in 
COJ1Jb.irw.tion with another drug, it -was possible to determ:'.ne 
whether a "chemical" (i.e., nonvisual) incompatibility might 
have occurred as a re.sult of the admixture.. Any alteration 
in the shape or structure of the spectrum, such as the add.i-
tion or deletion of a peak, ~las considered to represent a 
probable chemical incompatibility. By comparing the magni-
tude of absorption at the wavelength of maximum absorbance 
with the Beer's plot for the drug, it was also possible to 
determine whether the potency of the individual drugs might 
have changed follo1~ing admixture. A concentration loss of 
10 percent or greater was considered to be significant. 
This loss in potency has been advocated. as a standard for 
the limits of loss of potency for a drug (75). Spectra were 
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Graph 5. Beer plot for Sodium Cephalothin ( Amax 236 mr) 
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Graph 6. Beer plot for Vincristine Sulfate (A max 256.5 mp) 
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obtained. at 1, 4, ancl 8 hour intervals to determine whether 
time would have an influence on the compatibility and sta-
bility of the d.rugs in aclrnixture. Table III summa:r·:\.7..es the 
results of the study using the spectrophotometric analysis 
technique. 
Prednisolone sodium phosphate and 5-fluorouracil 
were added to 5 percent Dextrose Injection to yield con-
centrations of 200 mcg./ml. and 250 mcg./ml. respectively. 
These concentrations were consiclered to be v;ithin thera-
peutic range, calculated on the basis of' a 70 Kg. pernon 
receiving tbe drugs over a 21> hour period in three d.ivided 
doses, each of which was to be delivered in 500 ml. of 
intravenous fluid. 'l'he basis for this decision is sum-
marized as follows: 
Usual Dose: 
Dose for 70 Kg. 
Dose for 8 Hrs. 
Therapeutic Cone. 
Prednisolone 
Sodium 
Phosphate 
10-400 mg./daya 
10-400 mg./day 
3.3-133 mg. 
200 mcg./ml. 
5-l!'luorouracil 
5-15-mg./Kg./dayb 
350-1050 mg./day 
117-·350 mg. 
250 mcg./ml. 
Since both drugs vJere available from the manufac-
turer in solution form, neither required reconstitution. 
a - Product Information, Merck Sharp & Dohme, Division of 
Merck & Co., Inc., \vest Point, Pa. 
b- Product Information, Roche Laboratories,Division of 
Hoffmann La-Roche, Nutley, N. J. 
-
;;;; __ _ 
In order to obtain an absorption spectrum for each 
of the drugs, it was necessary to dilute the therapeutic 
concentrations for scanning. The final dilutions resulted 
in a concentration of 8 mcg./ml. for prednisolone sodium 
phosphate and 10 mcg./ml. for 5-fluorouracil. Aliquot 
dilutions v1ere done for each reading at the 1; '-e, and 8 
hour intervals" 
of the admixture was compared with the standard spectrum 
for the individual agents (:B'igures 1, 2, and. 3). The 
absorption spectrum for each of the drugs did. not appear 
50 
to be significantly altered either in shape or in degree of 
absorbance. 
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ADMIXrP.URE //2 5-FLUOROURACIL--NETHOTREXATE SODIUfi 
ln the following admi;..-ture, 5-fluorouracil was 
ad.dec1 t;o methotrexate sodium. 'L'he concentration used 
''•OJ:' r -f-' 1 "''T'O"'I'~('l.l '•Ia~ 250 me~ /m} .L ,../ .. .!..<..<.'.)_. v .. 0.. ,_ \' o;.) • __ ().:> ·• The concentration 
used for methotrexate sod_ium (200 mcg,/ml.) vms calcu-
J.ated on the following basis for a person receiving the 
tlrug over a 2.4· ho·clr period in three divid.ec1 doses, each 
-------».f_-wbich to be d.elivered in 500 mL of intravenous fluid: 
" II l 
" !
I 
i 
I 
J 
_:1 
Usual Dose Recommend.ed 
Dose for 70 Kg. Adult 
Dose .for 8 Hr. Period 
Thert-:q;->elrf;J.G Gone,, Used 
Methot·rexate Sodium 
2 mg./Kg.~·L> mg./Kg. a 
lLJ-0 mg./dtly-280 mg./day 
LJ-'7 mg.-93 mg. 
200 mcg./ml. 
Oommord.ally EnraiJ.able methotrexate scd.iu1:1 1.s 
supplied in an aqueous solution form, therefore, no pre-
lim.inary reconstitution of the product was needed. 
The concentration of each drug in the admixture 
resembled a therapeutic quantity such as might be used 
·in the clinical environment. Because these therapeutic 
concentr·ations were too great for spectrophotometric 
analysis, further dilution was necessary. At each test 
period indicated, appropriate d.ilutions were done so that 
the drugs eould be scanned. The final concentrations of 
the dilutions used to obtain the spectrum of each drug in 
the admixture vwre for methotrexate sodium 8 mcg./ml. and 
a - Product Information, Lederle Laboratories Division, 
American Cyanamid Company, Pearl River, N. Y. 
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for 5-fluor.ouracil 10 mcg./ml. 
In stud.ying the resulting spectra by comparison to 
the reference or standard spectra and the Beer plots for 
each of the drugs, it was quite apparent that alterations 
in shape and. magnitude of the absorption spectra had 
definitely occurred. From the onset of this study through·· 
out the eight hour period, significant constant structural 
------"~.U1B.ng " in the spectrum of methotrexate sodium were noticeo.~ 
with the establishment of a new peak. 5-l?luorouracil, on 
the other hand, yielded a slight shift in its A max and a 
significant increase in absorbance. The results of this 
study \Vould indicate the likely presence of a chemical 
interaction behveen these two d.rugrJ 11hen in an admixture. 
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ADMIXTURE #3 .2::_li'LIJ_OHOURACI~,-CYTARABINE 
5-Fluorouracil, 250 meg ./ml. and c;ytarabine, 
LJ-00 mcg./ml., were mixed in 5 percent Dextrose Injection. 
5-J!'luoroura.cil was added to the cytarabine at concentra-
tions which might be used therapeutically. The concen-
trations of the 5-Fluorouracil W<:ls determined as in 
Admixture #1. 'l'he concentration of c;ytara.bine \~aB es·cab-
lisl!ed accordJ.ng to a total daily dose divided into three 
portions, each delivered in 500 ml. of intravenous fluid: 
Usual Dose Recommended 
Dose for 70 Kg. Person 
Dose fo:e 8 Hr. Period 
Therapeutic Cone. 
C;ytarab:i.ne 
0.5-3 mg./Kg.a 
3.5-210 mg./day 
11.7-70 mg. 
400 mcg./ml. 
59 
Since cytarabine is obtained. in a lypholyzed state 
from the manufacturer, it was reconstituted according to 
the manufacturer's recommendations using the accompanying 
diluent. 
In or·der to obtain an absorption spectrum for each 
of the d.rugs, it was necessary to dilute the therapeutic 
concentrations to lower concentrations to permit scanning 
within the limits of the spectrophotometer. Final dilutions 
\•;ere made to provide concentrations of 10 mcg./ml. for the 
5-fluorouracil and 16 mcg./ml. for the cytarabine, 
The absorption spectrum for 5-:fluorouracil 
a - Product Information, The Up,john Company, Kalamazoo, 
Mich. 
-I 
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throue;hout the eight hour period was essentially unchanged. 
However, the ultraviolet absorption spectrum for the 
cytarabine was slightly changed by an alteration in thG 
initial loop of the spectrum. 'J~hGre appeared to be no 
chanr:;e in the main absorption peak or A of the spectrum. max 
Nevertheless, this might be an indication of a change in 
the chem:Lca.l structure of the drug. (Figures ? , 8) 9) 
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ADIY!IXTURE f/L~ J'HEDNI§OWNJ~ SODIU111 PHOSPHATE--CYTARABI]:TJ.! 
The figures for the following study inclucle the 
spectra from the admixture of pred.nisolone sodium phosphate 
and. cytarabine. The concentration used. for the .former drug 
vias 200 mcg.,/ml. and for the latter vms 400 mc:g./ml. Both 
concentrations wex•e considered to be \\!'ithin ther'8.peutic 
range for an average adult. In this admixture~ the 
in the infusion fluid. 
Because the solutions at therapeutic concentrations 
of these drugs \~ere too dense optica.lly to be scanned by 
the spectrOJ)hotometer? dilutions of the admixtures were 
n.ecessa . .r;y, 'l'he final dilutions re:Julted in concentrations 
of 8 ~cgt>/ml .. for the prednisolone sodium phosphate and of 
16 mcr;./rnL for the cytara.bine. These dilutions vlere pre-
pared for each readings at the 1, ~~. and 8 hour intervals. 
'Xhe absorbance for each drug was not significantly 
decreased, and neither spectrum was altered during the 
eight hour period. It would appear that this admixture is 
compatible and no chemical or physical incompatibility 
occurs when these two drugs are mixed together in 5 percent 
Dextrose Injection. (l!'igures 10, 11, 12) 
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ADIUXTUHE i(i5 5--FUJOHOtJHACJL---SODIU!1 CEPHAWTHIN 
~ ----------------
In the follo\Ving admh .-ture, 5-fluorouraci.l, 
500 mcg./ml. vms added to sodium cephalothin, 1,000 
mcg,/ml. The lare;e doses normally used for sodium 
cephalothin (from 500 mg. to 4- Gm. per I.V.) necessi.-
tat;ed using a concentration of 5-fluorouracil double 
that used. previously in this study. In order to d.ilute 
obtain a concentration for both drugs from which an 
absorption could. be obtained, it was necessary to increase 
the concentration of the .5-fluorouracil to approximate 
the concentration used for the sodium cephalothin more 
closely, 
Si.ncte EOdium cephalothin ':laS available only in 
68 
the dry powder form, it \•ras reconstituted according to 
the manufacturer's recommendations using 10 ml. of Sterile 
Water for Injection as the diluent. 
The therapeutic concentration used for the sodium 
cephalothin was decided upon arbitrarily using a lower 
convenient dose of 500 mg./500 ml. or 1,000 mcg./ml. 
Aliquot portions of the therapeutic admixtures 
were used for the final dilutions that could be scanned 
by the spectrophotometer. The concentrations of the dilu-
tions v1ere for the 5-fluorouracil, 10 meg. /ml. and for the 
sodium cephalothin, 20 mcg./ml. 
Admixture analysis revealed no significant decrease 
in the absorbance. of either drug and no apparent alteration 
69 
i.n the speetra when comparecl to the reference spectra. 
There also were no visual signs of any incompatibility. 
It would appear that this admixture combination is 
physically and chemically compatible. (Figures 13, 14-, 15) 
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ADIVJIXTURE 0'6 PRJIDNISO.Wlim SODIU!Vl PHOSPHA'l'E--r·mTHOTREXA'rE 
Preparation of the fol1o1'1ing admixture consisted 
of adding pred.t'"l.isolone sodium phosphate, 200 mcg./m1. to 
methotrexate sodium 200 mcg./m1. As before, both \'!ere 
considered therapeutic concentrations that might be used 
in the clinical situation. 
?3 
Again 1 due to the limitations of the spectrophoto·· 
-
~-
_____ mm"'d:_B:t' in preventin~ the use of these solutions cUrectl;w, ______ _ 
appropriate dilutions were made in order to obtain an 
absorbance spectrum for each of the clrugs in the admixture. 
The dilutions resulted in the follOiving concentrations for 
each of the drugs: prednisolone sodium phosphate, 8 mcg./ml. 
and methotrexate soclium, 8 mcg./ml. Thes(l dilutions were 
done from the therapeutic admixtures just prior to each of 
the readings at the 1, '-1-,. and 8 hour intervals .. 
Analysis of the admixtures through the use of the 
spectrophotometer revealed no significant change in the 
absorbance of methotrexate sodium comparing the primary 
peak of the standard with the primary peak of the reference 
spectrum. There was, however, an alteration or shift in a 
secondary peak of the methotrexate sodium spectrum. For 
the prednisolone sodium phosphate, the absorbance increased 
unexpectedly v/hen in the admixture. Both alterations 
occurred in the initial admixture and remained throughout 
the eight hour period. (Figures 16, 17, 18) These changes 
would be indicative of a change in the chemical nature or 
structural integrity of the additives and should be 
74 
considered to be a chemical incompatibility. There were 
no visual signs of any "physical" incompatibility. 
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AD~1IX1'URE #7 l\f.!','THCQ'REXATE SODIUIVJ--CY1l'ARABINJ2 
Ac;ain using Dextrose 5 percent Injection as the 
vehicle, methotrexate sodium was add.ed to cytarabine using 
the:mpeutic concentrations of 200 mcg./ml. aml Li.OO mcg./ml. 
respectively. 
Appropriate dilutions were made so that the absor-
bance of each drug \vould be within the range that could be 
scanned b;r the spectrophotometer. The concentrations of 
the dilutions \vere the following: methotrexate sodium, 
8 mcg./ml. and cytarabine 16 mcg./ml. These dilutions were 
made from the therapeutic admixtures just prior to the 1, Li., 
and 8 hour recordings. 
Vlhile slight alterations in the spectrum of 
methotrexate sod:::um v;crG observed~ the chang0s did :not 
appear to be significant. 1J'here did appear to be. a slight 
shift in the A max of the. drug; however, this change \vas 
somewhat questionable. There was no apparent change in the 
spectrum or in the absorbance of cytarabine. (Figures 19, 
20, 21) 
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AD~1IXTUHE //8 CY'TARABINE---SOl~IU~l CEPHALOTI!fU. 
In t'he following admixture, cytarabine was added 
to sodium cephalothin. The therapeutic concentrations 
used were the following: cytarabine 800 mcg./ml.. and 
sodium cephalothin 1,000 mcg./ml. 'The concentration in 
this admixture for cycarabine was double that v1hich had. 
been used in previous admixtures. This wa.s done because 
which was necessary to simulate normal therapeutic coneen-
trations of that drug. To facilitate dilutions that were 
necessary, it was required to use a concentration of 
cytarabine that at least somevlhat approached that of the 
sod.ium cephalothin. 
After preparing the di:Lutions to obtain an ultra-
82 
violet speotr•um for each of the ·b;o drugs in the admixture, 
the resulting concentrations wer•e 16 mcg./ml. for the 
cytarabine and 20 mcg./ml. for the sod.ium cephalothin. 
Comparison of the absorption spectrum of each of 
the additives in the admixture with the. respective reference 
spectra demonstrated no alteration in shape nor any appre-
ciable loss of absorbance. Throughout the eight hour perioa. 
there was a slight decrease in the absorbance for cytarabine; 
ho-vrever, this was not significant when evaluated in terms of 
the Beer plot. 
The data obtained from this admixture would seem to 
indicate the absence of any chemical interaction between 
these two drugs and this admixture woula. appear to be 
83 
compatible.. (Figures 22, 23, 2Le) 
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ADl'lrA'l'UHJ~ 1,19 PREDNISOIJONE SODIUM PHOSPHATE--SODIUI-1 CEPHAWl'HIN 
----~ -~- ---------
An acLmixture containing therapeutic concentrations 
of prec1n:i.solone sodium phosphate, 400 mcg./ml. and sodium 
cephalothin, 1 ~ 000 meg. /ml. waG prepared by ad dinE; the 
preonisolone sodium phosphate~ to the sodium eephalothin in 
5 percent Dextrose Injection. As mentioned in the descrip-· 
tion of adm:i.:-,_>ture 71'5, it was necessary to increase the con-· 
centra.tJ.on of the predlns ol one s od:i::urrrplTCFo'JYl:rat-e-t-c----:fuc:i.-:lcit--sc&cJ------
dilution of t;he sodium cephalothin to a concentration that 
coulo. be scanned. The concentration of the prednisolone 
sodium phosphate used was double that was used in the earlier 
To obteU.n the spectrum for each of the drugs, appro-· 
pr:i.ate c1ilutions were made to achieve a final concentration 
of 8 racg./ml. for the preo.nisolone s.odium phosphate and 
20 rilcg./ml. for the sodium cephalothin. 
An interpretation of the spectra over the eight 
hour period revealed no alteration in their shapes nor in 
their absorbances 1-1hen compared to their respective standards. 
As there we:r.•e no noticeable changes, the admixture was assumed· 
to be chemically and physically compatible. (Figures 25, 26, 
27) 
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ADMIX'l'URE //10 J'lETHO'l'REX:ATE SQJ2IUIYI--SODIU!Il CEHiHO'rHIN 
Preparation of the follO\,Jing admixture consisted 
of adding methotrexate sodium to sodium cephalothin. The 
concentrations used, which simulated those use(l in actual 
clinj.cal medicine, were methotrexate sodium 400 mcg./rnl. 
and .sodium cephalothin 1,000 rncg./ml. Again, the concen-
trati.on :for the methotrexate sodium VIas increased (double 
91 
peutic concentrations used in medicine with sodium cephalothin. 
As was the case in the previous expe:riments, due to 
the limitations of the spectrophotometer's preventing the 
use of the above solutions directly, dilution of the initial 
adnli.xtures was necessary. The resulting concentrations after 
final dilution vl/ero 8 mcg"/ml" f'or the methotrexate sodium 
aml 20 mcg.,/ml. for .the sodium cephalothin. 
During the eight hours of the study, neither spectrum 
was altered. and there was no noticeable decrease in the 
absorbance, \vhen comparing the spectra ~Jith their respective 
references. (Figures 28, 29, 30) 
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ADHIXTURE 1lll METHOTBKXAT~·--VINCRISTINE SUlFATE 
A special problem was encountered in preparing an 
admixture of methotrexate sodium and vincristine sulfate 
because of the extremely small doses o.f vincristine sulfate 
normally emplo;y·ed in clinical medicine. For this particu-
lar additive, the usual recommended therapeutic concentra-
tion \·la.B also the optimum concentration for· speetrophoto-· 
In order for both drugs to be mixed together and 
still obtain optimum spectrophotometric concentrations for 
each drug, different dilution techniques were employed.. A 
single component admixture of methotrexate sodium in 5 per-
cent Dextrose Injection was pr0pared having a concentration 
Vincristine su.1fate was reconstituted with the 
accompanying di1uent according to the manufacturer's recom-
menda.tions. A dilution of vincristine sulfate \•Jas prepared 
to y:Le1d a concentration of 4 mcg./ml. To this solution 
an aliquot amount of the methotrexate sodium solution was 
added to proa.uce a concentration of 8 mcg./ml. in the admix-
ture. \'lh:i.le this technique did not simulate actual clinical 
practice, this method was employed nevertheless >vith the 
hope that useful compatibility information could be obtained. 
The concentration used. for vincristine sulfate was 
calculated on the following basis for a 70 Kg. person receiv-
ing the drug over a 24 hour period in three divided doses, 
each of which to be a.eliverea. in 500 ml. of the intravenous 
li 
fluid: 
Usual Recommended Dose 
Dose for 70 Kg. Adult 
Dose for 8 Hrs. 
Therapeutic Cone. Used 
96 
Vincristine Sulfate 
0.05 mg,./Kg.-0.1 mg./Kg.a 
3.5 mg./Kg./Day-7.0 mg./Kg./Day 
1.17 mg.--2.33 mg. 
4 mcg./mL 
The results of the analysis of the spectrum obtained 
~Ei'~f_j;_b_a_ilrngs_in _ _t_he admixture incl.ica.ted that there 
did not appear to be any alteration in either shape or any 
decrease in absorbance. (Figures 31, 32, 33) 
a - Product Information, Eli Lilly, Indianapolis, Ind. 
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AD!UX'l'URE ;;112 C:;ITARA81N_l~:--.. VIN..Q.BJ:§22]::tm SUI,FA'l':§ 
In this admixture, eytarabine was added to 
vincristine sulfate. As vJi th the previous admixture, 
dilution procedures were somewhat modified. A single 
component admixture o.f cytarabine in the infusion fluid 
was prepared which had a resulting concentration of 
L~OO meg. /ml. After reconstitution, a.· solution of 
vj ncristine sulfate was macte ,,Ji th a resulting concen--
100 
tration of 4- mcg./ml. To the vincristine sulfate solution 
v.ras added an aliquot portion of the eyl~arabine solution 
to proo.uee a final concentration of cytarabine of 16 mcg./ml. 
in the admixture. The solution was then sca.rmed and the 
spectrum J or• eaeh o.rug waB ana.ly:-,ed for any sign of a chemJ.-
eo.l ineorr1pat-:i bili t;y"' 
For each of the t~10 dr'Ugs in the admixture, the 
absorption spectrum vms compared with its respective 
reference standard. Since, throughout the eight hour study, 
the l.lltraviolct absorption spectrum for the tvw drugs 
appeared not to be altered, it would. appear that the two 
drugs are chemically compatible in admixture. (Figures 34, 
35, 36) 
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ADHIX'rUHE iJl3 5-·J.IHJOHOUHACIL·--VINCHIS'l'INE SULJ.IATE 
In the last of the admixtures clone in this study, 
5-fluorouracil. was added to vincristine sulfate. As was 
mentioned before, the.admixture techniques when using 
vincristine sulfate were modified. A single component 
admixture of 5-fluorouracil in the 5 percent IleA->trose 
Injection was made to give a concentration of 500 mcg./ml. 
tration of LJ. mcg./ml. '.l'o this latter solution, an aliquot 
amount of the 5-fluorouracil solution was added to give a 
concentration of 10 mcg./mL. in the admixture. A spectrum 
for each of the two drugs in the admixture was then obtained 
1~i th t!:te· Dpectrophotometer. 
A1thot:.gh the absorbance of the 5-·fluoroura.cil 
decreased slightly over the eight hour period, the decrease 
11as not significant and the spectrum for 5-fluorouracil 
remained essentially unchanged. The absorbance and the 
spectrum for the vincristine sulfate remained unchanged 
through the study. This would tend to indicate that there 
is no chemical. incompatibility when 5·-fluorouracil is mixed 
with vincristine sulfate. (Figures 37, 38, 39) 
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TABLE III (CONTTIJUED) 
Admixtures a 
~--
-- a: 
Concentration (mcg./ml.)c Max Spectrumef 
Therapeutic Dilution Scanned 
11. Methotrexate Sodium 
Vincristine Sulfate 
8 
4 
8 
4 
302 no change o 
256.5 no change 
12. Cytarabine 
Vincristine Sulfate 
16 
4 
16 272 no change 
4 256.5 no change 
13. 5-Fluorouracil 
Vincristine Sulfate 
10 
4 
10 
4 
265.5 no change 
256.5 no change 
a 
b 
In the follmving admixtures, the first drug listed. in the combinatio)L pair was added to the 
second drug listed. J 
Higher therapeutic concentrations of these drugs were used v1hen mixea_ "'ith sodium cephalothin in 
order that both drugs in the admixture could be spectrophotometrical~.y measured after proper 
dilution. 
c - Dilutions of the o.rugs from their therapeutic concentrations v?ere neqessary in order to achieve 
concentrations that could be spectrophotometrically mBasured. 
d - The values listed for the A max for each of the drugs are those that l•·1ere obtained by measuring 
each drug alone in Dextrose 5 percent Injection. 
e -
f -
I I 
The spectrum for each of the drugs in the combinations was considerel altered if there was a 
significant loss (greater than 10 percent) in absorption of the drug or if there vms an appre-
ciable change in the shape or structure of the absorption spectrum. 
No physical or visual incompatib:Uities t'l7ere noticed in any of the a mixtures that might have 
been determined by a color change, precipitation, cloudiness, or gas !evolution. 
If I 1]: ~- IIIII 1- I, 
,__, 
0 
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CHAPTER IV 
DISCUSSION 
In reviewing the results of this experiment, it is 
apparent that there. may be chemical incompatibilities among 
certain of the oncol;ytic agents tested when mixed tog,~e-"t""h".ec-r,__ __ _ 
with themselves or with cephalothin sodium or prednisolone 
sodium phosphate in intravenous solution, using 5 percent 
Dextrose Injection as the infusion vehicle. 
The findings demonstrated definite spectral altera-
-tions of both! d.rugs when 5-fluorouracil \11/'lS added to 
I 
I 
methotre:::.::ate Sodium. The changes in the speetra of the 
' 
drugs in this! admixture were the most noticeable of any of 
! 
the admixtures throughout the entire study. The increase 
in the absorb~nce of 5-fluorouracil we.s quite apparent, 
' however, the clinical significance of this is not clear • 
. ~ 
It would appear that the change is related to a chemical 
I 
change in the'chemical structure of the drug. The changes 
i 
in the spectr~m of methotrexate sodium were quite startling. 
Chemical alterations in the struciure of the drug are prob-
i 
ably the cause of the changes that were noted in the spectrum 
! 
of methotrexate sodium when it was combined with the 
5-fluorouracil. On the basis of these results, it is advised 
that this combination of drugs not be mixed together in an 
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I.V. bottle. 
A change 1~as observed in the spectrum of 
prednisolone sodium phosphate when it was added to 
methotrexate sodium. The spectrum of methotrexate 
itself was-altered to a lesser extent. Therefore, in 
the interest of the chemical integrity of both of these 
drugs, use of this combination should. be approached with 
caution. 
While only slight spectral changes 1•1ere noted in 
methotrexate sodium when it was added. to cytarabine, it 
is important to keep in mind that 1:1hile these alterations 
appeared to be only relatively small, significant chemi-
cal and hence; possibly significant therapeutic changes 
might have occurred. 
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In the admixture in which 5-fluorouracil 1vas add_ed 
to cytarabine, no alteration was observed in the spectrum 
for the 5-fluorouracil-component. However, there was a 
somewhat noticeable change in the spectrum for the cytara-
bine. Again, the compatibility of this combination in 
admixture may be ope~ to some question, and if possible, 
the mixing of these drugs in an I.V. bottle should be 
discouraged. 
It is of interest to note that in those admixtures 
in vrhich vincristine sulfate and sodium cephalothin were · 
included no significant or apparent alterations in spectra 
were noted. Also, when prednisolone sodium phosphate 1·1as 
added to 5-fluorouracil and to cytarabine, no chemical 
interactions or incompatibilities were noticed. From the 
results of this study, it appears that the combining of 
these drugs in 5 percent Dextrose Injection in admixtures 
does not result in any "visual" or "physical" or chemical 
incompatibilities. 
· It was mentioned earlier that little work had 
previously been done in the area of intravenous incom-
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patibilities involving anticancer drugs. One reference,, _____ _ 
mentioned earlier, is applicable to the results of this 
study. In the compatibility table ~1hich 1~a.s compiled by 
the Pharmacy Department at the National Institutes of 
Health, it is stated that methotrexate sodium is compatible 
1~ith vincristine sulfate (74). The work done in this study 
would further verify that statement. It is unfortunate 
that in their compatibility table, no mention was made to 
indicate how compatibility was determined. 
Although not found in the literature, personal 
correspondence of the author \lith the Pharmacy Department 
at N .I.H. indicated that the admh.'ture of methotrexate 
sodium and prednisolone sodium phosphate ~ms incompatible. 
Again, the results of this experiment, in Admixture #6, 
would tend to confirm that fact. 
Out of the four admixtures in which some spectral 
change \'laS observed, it is of interest to note that 
methotrexate sodium was involved in three, and 5-fluorouracil, 
prednisolone sodium phosphate, and cytarabine in one admix-
ture. Two of the drugs in this study, as mentioned above, 
i 
., 
I 
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did not appear to be involved in any chemical or physical . 
incompatibility. 
Because methotrexate sodium was the drug most fre-
quently involved in the admixtures whose additives sh01o1ed 
altered spectra, and because of the significant ohanges 
that were noted when 5-fluorouracil \vas added to 
methotrexate sodium, it was decided to examine.this par-
ticular combination of drugs more closely. This was in 
an attempt to further demonstrate and validate that an 
incompatibility does exist when methotrexate·sodium and 
5-fluorouracil are mixed together in an intravenous solution. 
It was hoped that by employing a different methoo. of detect-
ing chemical interactions, such as through the demonstration 
of an altered or breakdov;n product <J that the results of the 
spectrophotometric analysis would be confirmed and firmly 
substantiated. Since, in Admixture #2, the spectrum of 
methotrexate sodium demonstrat.ed the greatest alteration, 
it was decided to examine this drug, alone and in the com-
bination with the 5-fluorouracil to further establish that 
a chemical change had occurred. 
Only a few other examples of other possible and 
practical methods of examining methotrexate sodium in an 
admixture 1·1ere found in the literature. Most of these 
involved elaborate procedures employing complex chemical 
techniques such as fluorometroscopy (76), microbiological 
assays (77,78), spectrofluorometry (79), and chromatography 
(80,81), as well as the u.s.P. method of ultraviolet 
spectrophotometry (82). These papers describing methods 
of column and. paper chromatography expressed several 
limitations to such techniques. Therefore, a novel tech-
nique was attempted utilizing thin-layer chromatography 
because of its suitability, relatively easy application, 
and \•li.de'usage in other assay procedures (83,84-). 
Since no previous assay method for methotrexate 
sodium (or for 5-fluorouracil) using thin-layer chromatography 
could be found i.n the literature, techniques and materials 
were devised on an empirical basis. Using a variety of sol-
vent systems on three <Efferent adsorbants, attempts were 
made to find a combination which would result in different 
Rf values or chromatograms for methotrexate sodium and 
5-fluorouracil. It \vas hoped that the two COffiJjounds could 
be distinguished and identified. 
Eluotropic systems for this phase of study included 
solvents with various a.egrees of polaritybased on available 
tables that provided a breakdown of the eluting po;ver of 
certain solvents (85). Also, includ.ed .were eluotropic 
systems with different degrees of acidity and alkalinity. 
Combinations of solvents were selected on the basis of pre-
dicted utility for these drugs. Trial adsorbants included 
activated silics gel, activated alumina, and cellulose. 
These were tested in order to experiment 1vith adsorbants 
of different strengths of adsorbing pmqer. 
Thin-layer chromatography \vas applied to methotrexate 
sodiUm and 5-fluorouracil in solutions by themselves as well 
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as an admixture of the two drugs. After. spotting the p:I.ates 
and allo1ving the solvent· systems to ascend 10 em., the 
plates were allowed. to dry before being developed ~lith a 
spray of either potassium permanganate 0.05 percent in 
water or a miJ...'ture of potassium permanganate 1 percent and 
sodium carbonate 5 percent in water. After extensive 
attempts of testing, including attempts at t\-10-dimensional 
thin-layer chromatography, no combination of solvent system 
and adsorbent could be. found that would adequately separate 
and, therefore, distinguish the two drugs, alone or in the 
admixture. 
Approaching the incompatibility problem of 
methotrexate sodium and.5-fluorouracil from a different 
point of view, another methoil. was sought that l'rould S'~b­
stantiate the results of the spectrophotometric analysis. 
It was reasoned that if an ·alteration in the spectrum of 
the two drugs resulted only from the change in the pH of 
the admiJ...'ture, the original spectrum should again be 
attained by simply readjusting the pH of the admixture 
back to the original pH of the reference solutions of each 
drug. If the. original spectra could not be attained by 
this method, then it could be concluded that the altera-
tions that occurred in the spectra were of a permanent 
nature indicating a change in the chemical nature of the 
t1-10 drugs. 
In an attempt to test this theory, the admixture 
(see Admixture #2) was repeated, including preparation of 
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the reference solutions. The pH of each of the solutions 
was measured using a Radiometer pH ~1eter 25 SE Expanded 
Scalea model to first see if there existed any differences 
in the pH of the reference solutions of each of the drugs 
and the adJTii:x:ture solution. The results of the pH readings 
are shovm on the follo\'ling table. 
TABLE IV 
t-------------------------------~---------
1 
I 
'I I, 
II li 
Change in pH When 5-Fluorouracil Has Added to 
Nethotrexate Sodium in 5 Percent Dextrose Injection 
Drug 
11ethotrexate Soc1:ium 
5-Fluorouracil 
5 Percent Dextrose Injection 
Admixture (Therapeutic Cone.) 
~lethotrexate Sodium 
5-Fluorouracil 
Admixture (Scanning Dilution) 
r1ethotrexate Sodium 
5-Fluor~:mracil 
Concentration 
(mcg./ml.) 
200. 
250 
200 
250 
8 
10 
pH 
6.87 
8.51 
4.5 
8.4 
7.2 
From the data above, it is seen that there were indeed 
pH changes in the admixed solutions. It was thought that 
there might be some possible correlation bet;.;een the results 
a - Radiometer, Copenhagen, Denmark. 
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obtained >vith the use of the spectrophotometer and the 
changes in pH. It is of intere_st to note that the pH of the 
admixture was very close to the pH of the 5-fluorouracil 
reference solution and it was quite different from the origi-
nal pH of the methotrexate sodium reference solution indicat-
ing that the buffer capacity of the 5-fluorouracil was 
stronger than that of the methotrexate sodium. 
In the next step of the attempt to correlate changes 
in pH with the alteration in the spectrum of methotrexate 
sodium, a solution of methotrexate sodhun was made in a 
buffer solution \\Those pH approximated the pH of the admix-
ture. This buffer solution was an alkaline borate buffer of 
pH 8.2 (76). The concentration of methot:vexate sodium used 
1·1as the same o.s before~ 200 mcg .. /ml., and the pH c.f the 
resulting solution was pH 7.85. It was thought that if the 
same altered spectra were obtained in the buffered solution, 
the spectral alteration ~1ou1a. probably be due to the change 
in pH. After scanning this solution with the spectrophoto-
meter, the same altered spectrum of methotrexate sodium ~1as 
obtained as occurred vlhen in the admixture with 5-fluorouracil. 
To carry this experiment out one step further, the 
pH of the buffered solution of methotrexate sodium was lowered 
in a step-~1ise manner, using 0.2M HCl, to a pH that was 
approximatel~ the same as the pH of the methotrexate sodium 
reference solution. Using 0.211 HCl, the pH of the buffered 
solution was lowered to pH 6.55 and a spectral scan of the 
solution was obtained. Although some error was introduced 
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here in d.iluting the original solution 1vith the volume of 
acid, the principal objective of this manipulation vJas to 
lower the pH of the buffered solution to a pH similar to 
the pH of the reference solution. This was done to deter-
mine whether the altered spectral occurring at the higher 
pH would revert back to the orignal spectrum. The result-
ing spectrum appeared not to change significantly from the 
altered. scan, indicating possibly that, at the higher pH, 
an irreversible chemical change occurred. These results 
would tend to indicate that the change noted in the spec-
trum of methotrexate sodium, when it 1vas combined 1vith 
5-fluorouracil in an admixture, was due to the change in 
pH of the methotrexate soc1ium. While not· conclusive, :Lt 
would also indicate that this chemical change is probably 
not reversible. These results are further substantiated 
by the results obtained by Hayden and co-workers (87) who 
observed different ultraviolet absorption spectra for 
methotrexate in O.lN HCl ()\max 306 mu) and in O.lN NaOH 
( Amax 301 mu). 
It is of interest to note that, chemically, 
methotrexate represents an amphoteric substance in that 
it contains t1v0 basic amino groups and two acidic carboxyl 
groups. The chromophores may undergo change at different 
pH values and are most likely the cause in the changes in 
'the spectrum of methotrexate sodium. 
Although this method may have lacked accuracy, it 
did help to understand more completely, in one particular 
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case, the probable cause of the alteration of the spectrum 
of methotrexate sodium when in combination with 5-fluorouracil. 
Considering briefly the alteration in the A max that occurred 
in the spectrum of 5-fluorouracil, it is of interest to note 
that the 5-halogenuracils, in general, have been reported 
to shov·l a bathochromic effect, that is, a decrease or shift 
in the A of the ultraviolet absorption spectrum in max · 
response to pH changes. 5-Fluorouracil has been sho~m to 
demonstrate onl;J' a slight bathochromic shift (88). The 
significance of this, in respect to the effect this might 
have on its therapeutic efficacy, is uncertain. 
The variables and limitations of absorption spectro-
photometry in·detecting chemical incompatibilities of intra-
venous admixtures has been revietoJed by Catania (62).. In 
this study, the infusion fluid used was 5 percent Dextrose 
Injection. While this vehicle is the one most widely used 
in medicine for the purposes of delivering medications, 
other I.V. fluids may be used. With others, it is entirely 
possible that the results obtained from this study might be 
different. 
Limitations within the spectrophotometer itself 
could have had an influence on the results. It was noted 
that with sodium cephalothin, a certain amount of uncon-
trollable "noise" was obtained when scanning its spectrum. 
This "noise" was noticed ·in the region of X max of the 
spectrum and, therefore, might be a concentration dependent 
problem with this particular agent. 
While every attempt was made to use therapeutic 
concentrations of the ~rugs in the admixtures, in a few 
cases, for scanning, this was not possible because of the 
instrumental limitations. This difficulty necessitated 
dilution of the mixtures for evaluation. 
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CHAPTER V 
Sill'IMt1.RY AND CONCWSION 
Through the use of.a,.bsorption spectroscopy and 
visual observations, the compatibility of selected oncolytic 9 
antibiotic, and corticosteroid drugs Has determined. The 
six drugs used in this study included metho·trexate sodium, 
prednisolone sodium phosphate, sodium cephalothin, 
5-fluorouracil, cytarabine, and vincristine sulfate. These 
were cross-matched in pairs, utilizing 5 percent Dextrose 
Injection, as the vehicle. By obtaining the ultraviolet 
absorption spectrum of each of the drugs alone in the 5 
percent Dextrose Injection, reference or standard spectra 
v;ere obtained which could be used as a comparison for the 
spectra of the drugs in admixture. This comparison per-
mitted detection of any alterations inthe spectrum from 
the admixture which might have been manifested by a loss 
of absorbance of a major peak in the spectrum, the emer-
gence or disappearance of a peak, or in the general altera-
tion of the spectrum. 
The primary purpose of this paper 1vas to determine 
any chemical incompatibilities that might result from 
chemical interactions of the drugs in admixture. Four 
possible chemical incompatibilities were noted, \'lith one 
of the admixtures yielding significant alterations in the 
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absorption spectrum of each o.f the additives. None o.f the 
.four possible chemical incompatibilities displayed any 
signs o.f a visual or "physical" incompatibility. 
In conclusion, it can be said that spectrophoto-
metric analysis does provide a useful tool for the deter-
mination of incompqtibilities of intravenous admiA~ures. 
The results obtained here, however, can only serve as a 
guide to the clinician who wishes to mix drugs in the same 
infusion fluid. Further work in this area is still defi-
nitely needed and other methods of study need to be found. 
i1hile probably the ultimate test of a drug's integrity and 
therapeutic efficacy still lie in biological testing, these 
methods have not yet been adequately developed and severe 
limitations are placed on time. Microbiological testing 
of the potency of a drug becomes greatly complicated. and 
many other variables must be considered v1hen done in the 
presence of other drugs. It is in many cases inappropriate. 
It is hoped, as has been advocated by Donn (40), 
that the future of intravenous therapy will see a decrea:se 
in the number of I.V. admixtures used, and that attempts 
will be made not to admix drugs physically. 
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